Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Skedsmokorset – page 6

607 clinical trials in Skedsmokorset, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Skedsmokorset at a glance
607
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

607 trials in Skedsmokorset

Open in trial search

Safety and Tolerability of Tenofovir Alafenamide Dose Escalation in Healthy Adults for Epstein‑Barr Virus Infection

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tenofovir Alafenamide
  • Sponsor:Helse Bergen HF

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Lerodalcibep for Heterozygous Familial Hypercholesterolemia in Children and Adolescents 6 to 17 Years Old

Investigational
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Lerodalcibep
  • Sponsor:LIB Therapeutics Inc.

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

BMN 333 Versus Vosoritide in Children With Achondroplasia

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:BMN 333
  • Sponsor:Biomarin Pharmaceutical Inc.

AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Stomatitis+1

Recruiting

A study to compare the effectiveness of bupivacaine hydrochloride monohydrate and lidocaine hydrochloride for treating mouth sores in patients with head and neck cancer.

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bupivacaine hydrochloride monohydrate
  • Sponsor:OncoZenge AB

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Skedsmokorset

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on lipoprotein management and prevention of major cardiovascular events in patients with established cardiovascular disease.

  • Cardiovascular Disease Prevention
  • Lipid Management
  • Cardiovascular Event Reduction

Studies evaluating novel therapeutic approaches for reducing cardiovascular mortality and improving patient outcomes.

02 Stroke Prevention

Research examining new treatments for preventing stroke and systemic embolism in patients with atrial fibrillation, comparing innovative therapies with established medications.

  • Atrial Fibrillation Management
  • Anticoagulation Therapy
  • Stroke Risk Reduction

Trials focused on developing safer and more effective treatments for stroke prevention.

03 Vascular Disease Research

Studies investigating treatments for atherosclerotic cardiovascular disease, with emphasis on preventing major adverse cardiovascular events.

  • ASCVD Management
  • Cardiovascular Risk Reduction
  • LDL cholesterol Control

Evaluation of novel therapies targeting established vascular disease and its complications.

04 Pulmonary Medicine

Clinical research examining the effectiveness of combination therapies for Chronic Obstructive Pulmonary Disease, focusing on cardiopulmonary outcomes.

  • COPD Treatment
  • Respiratory Medicine
  • Bronchodilator Therapy

Investigation of advanced treatment options for improving respiratory function and quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.